Skip to main navigation Skip to search Skip to main content

A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial

  • William M. Hague
  • , Leonie Callaway
  • , Jennifer Chambers
  • , Lucy Chappell
  • , Suzette Coat
  • , Jiska de Haan-Jebbink
  • , Marloes Dekker
  • , Peter Dixon
  • , Jodie Dodd
  • , Maria Fuller
  • , Sanne Gordijn
  • , Dorothy Graham
  • , Oskari Heikinheimo
  • , Annemarie Hennessy
  • , Risto Kaaja
  • , Teck Yee Khong
  • , Laura Lampio
  • , Jennie Louise
  • , Angela Makris
  • , Corey Markus
    • Hanns-Ulrich Marschall, Philippa Middleton, Ben W. Mol, Jonathan Morris, John P. Newnham, Caroline Ovadia, Michael Peek, Antonia Shand, Michael Stark, Jim Thornton, Susanna Timonen, Susan Walker, David Warrilow, Catherine Williamson
  • Monash University

Research output: Contribution to journal › Article › peer-review

48   Link opens in a new tab Citations (Scopus)
10 Downloads (Pure)

Abstract

Severe early onset (less than 34 weeks gestation) intrahepatic cholestasis of pregnancy (ICP) affects 0.1% of pregnant women in Australia and is associated with a 3-fold increased risk of stillbirth, fetal hypoxia and compromise, spontaneous preterm birth, as well as increased frequencies of pre-eclampsia and gestational diabetes. ICP is often familial and overlaps with other cholestatic disorders.
Original languageEnglish
Article number51
Number of pages14
JournalBMC Pregnancy and Childbirth
Volume21
Issue number1
Early online date12 Jan 2021
DOIs
Publication statusPublished - 2021

Bibliographical note

Funding
The study sponsor and the funder (National Health and Medical Research Council (NHMRC) Medical Research Future Fund (MRFF) Lifting Clinical Trials and Registries Capacity (LCTRC) Grant Opportunity) have had no role in the study design; the collection, management, analysis, and interpretation of the data; the final writing of the report; and the decision to submit the report for publication.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Intrahepatic cholestasis of pregnancy
  • Cholestatic pruritus
  • Bile acids
  • Ursodeoxycholic acid
  • Rifampicin
  • Maternal and neonatal health outcomes

Access to Document

  • Hague_etal_BMCPC_A_Multi-Centre_Open_VoR

    © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/

    Final published version, 835 KBLicence: CC BY

    Fingerprint

    Dive into the research topics of 'A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial'. Together they form a unique fingerprint.
    View full fingerprint

    Cite this